Condition: Non Small Cell Lung Cancer · Glioma Glioblastoma Multiforme · Glioma, Malignant · Sponsor: Tango Therapeutics, Inc.
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
This description comes directly from the study's public registry record.
Tab Cooney, MD · (857) 320-4899 · clinicaltrials@tangotx.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Scottsdale | Scottsdale, Arizona, United States | Recruiting |
| University of California, Irvine | Irvine, California, United States | Recruiting |
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California at San Francisco | San Francisco, California, United States | Recruiting |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic Cancer Center | Rochester, Minnesota, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06810544